Asset Details
Do you wish to reserve the book?
2022-RA-685-ESGO What is beyond brca mutational status in high grade serous ovarian cancer? The role of hormone receptors expression
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
2022-RA-685-ESGO What is beyond brca mutational status in high grade serous ovarian cancer? The role of hormone receptors expression
Do you wish to request the book?
2022-RA-685-ESGO What is beyond brca mutational status in high grade serous ovarian cancer? The role of hormone receptors expression
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
2022-RA-685-ESGO What is beyond brca mutational status in high grade serous ovarian cancer? The role of hormone receptors expression
2022
Overview
Introduction/BackgroundSeveral studies have explored the prognostic role of hormone receptor status in high grade serous ovarian cancer (HGSOC). However, few reports have investigated their expression according to BRCA mutational status. Notably, there is evidences of a strong interaction between BRCA1/2 proteins and steroid hormones system, including higher titres of estradiol and progesterone in BRCA1/BRCA2 mutation carriers. Thus, we sought to explore the hormone receptor pattern and its potential prognostic impact in a well-characterized cohort of HGSOC patients stratified for BRCA status.MethodologyWe assessed ERα, ERβ1, ERβ2, ERβ5, PR (progesterone receptor) and AR (androgen receptor) expression by immunohistochemistry in a single-centre observational retrospective cohort study of 207 HGSOC women, profiled for BRCA-1/2 mutation status with available clinical and molecular features.Results135 BRCA-wild type (BRCA-wt) and 72 BRCA1/2 mutation carriers (BRCA-mut) were observed. No significant differences were detected in hormone receptor expression between the two populations. However, in the subgroup analysis according to menopausal status, a significantly lower ERα expression was found in pre-menopausal BRCA-mut compared to BRCA-wt patients (p=0.02) (figure 1). Regarding survival analysis, none of the examined hormone receptors had a significant prognostic role. However, a higher ERα/ERβ5nuclear ratio differently affected outcome according to BRCA status: positively in BRCA-wt cohort (HR 0.77; CI 0.61–0.96; p=0.019) and negatively in BRCA-mut cohort (HR 1.41; CI 1.06–1.87; p=0.020) (table 1). Finally, higher PR levels were associated with platinum sensitivity in the whole population (p=0.019).Abstract 2022-RA-685-ESGO Figure 1Abstract 2022-RA-685-ESGO Table 1Survival analysis on BRCA-wt vs. BRCA mutated (n=207)ConclusionThis study suggests a potential role of estrogen-mediated pathways in BRCA1/2-associated HGSOC tumorigenesis, revealing a possible therapeutic potential of targeting this interaction.
Publisher
BMJ Publishing Group Ltd,Elsevier Inc,Elsevier Limited
Subject
